Ginkgo Bioworks Quarterly Income Statement
NYSE: DNAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ginkgo Bioworks revenue and earnings
In the quarter ended Jun 30, 2026, Ginkgo Bioworks generated $20.2 million in revenue, down 48.5% from the same quarter a year earlier. Ginkgo Bioworks reported a net loss of $46.7 million, compared with a loss of $60.3 million a year earlier. Gross margin was 91.5% (up from 86.3%) and operating margin -290.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Ginkgo Bioworks income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.16M | 19.47M | 33.40M | 38.84M | 39.13M | 38.23M | 43.85M | 89.05M | 56.21M | 37.94M | 34.76M | 55.43M |
| Revenue growth (YoY) | -48.49% | -49.06% | -23.84% | -56.39% | -30.37% | +0.75% | +26.16% | +60.65% | -30.24% | -52.98% | -64.64% | -16.52% |
| Cost of Revenue | 1.72M | 3.10M | — | — | 5.38M | 4.09M | — | — | — | — | — | — |
| Gross Profit | 18.44M | 16.38M | — | — | 33.75M | 34.14M | — | — | — | — | — | — |
| Operating Expenses | 76.98M | 87.75M | 104.15M | 128.85M | 115.14M | 137.29M | 147.45M | 144.25M | 279.15M | 215.95M | 212.87M | 341.82M |
| Research & Development | 46.21M | 49.92M | 50.13M | 69.35M | 53.37M | 70.92M | 76.38M | 77.01M | 134.22M | 136.46M | 117.04M | 156.66M |
| Operating Income | -58.55M | -71.37M | -70.75M | -90.02M | -58.16M | -80.97M | -103.61M | -55.20M | -222.94M | -178.00M | -178.12M | -286.39M |
| Interest Expense | — | — | — | — | — | — | 31.37M | -9.25M | -10.31M | — | 44.01M | -15.02M |
| Other Income (Expense) | 1.35M | -4.76M | -10.64M | 9.26M | 4.69M | -2.25M | -4.25M | -1.57M | 5.95M | 12.12M | -33.77M | -16.52M |
| Pretax Income | -57.19M | -76.14M | -81.39M | -80.75M | -53.48M | -83.22M | -107.86M | -56.78M | -216.99M | -165.88M | -211.89M | -302.91M |
| Income Tax | 128.00K | -80.00K | -643.00K | 1.00K | -283.00K | 88.00K | -325.00K | -375.00K | 190.00K | 31.00K | -198.00K | -22.00K |
| Net Income | -46.71M | -82.59M | -80.75M | -80.75M | -60.30M | -90.96M | -107.53M | -56.40M | -217.18M | -165.91M | -211.69M | -302.89M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.75 | -1.39 | -1.41 | -1.45 | -1.10 | -1.68 | -1.92 | -1.08 | -4.23 | -3.31 | -11.96 | -6.21 |
| EPS (Diluted) | — | — | -1.41 | -1.45 | -1.10 | -1.68 | -1.91 | -1.08 | -4.23 | -3.32 | -11.96 | -6.21 |
| Shares Outstanding (Basic) | 62.09M | 59.56M | — | 55.63M | 54.86M | 54.24M | — | 52.24M | 51.37M | 50.11M | — | 48.77M |
| Shares Outstanding (Diluted) | — | — | — | 55.63M | 54.86M | 54.24M | — | 52.25M | 51.38M | 50.13M | — | 48.77M |
| EBITDA | -46.23M | -58.58M | -57.09M | -74.76M | -42.91M | -66.15M | -87.95M | -38.03M | -205.62M | -165.13M | -165.28M | -265.33M |
| Gross Margin | 91.47% | 84.09% | — | — | 86.25% | 89.30% | — | — | — | — | — | — |
| Operating Margin | -290.47% | -366.51% | -211.86% | -231.78% | -148.63% | -211.80% | -236.29% | -61.99% | -396.66% | -469.12% | -512.49% | -516.68% |
| Net Margin | -231.74% | -424.09% | -241.80% | -207.93% | -154.09% | -237.92% | -245.25% | -63.34% | -386.40% | -437.25% | -609.10% | -546.44% |
This table shows 12 quarterly periods of Ginkgo Bioworks's income statement, from Q2 2026 back to Q3 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow DNA's reporting calendar. What is a income statement?